查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1668079

双特异性抗体市场 - 全球产业规模、份额、趋势、机会和预测，按适应症（癌症、发炎和自体免疫疾病等）细分，按地区和竞争情况，2020-2030 年预测

Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球双特异性抗体市场价值为 68 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 9.40%。双特异性抗体是一类旨在同时针对两种不同抗原的治疗性蛋白质，为治疗各种疾病（包括癌症和自体免疫疾病）提供了独特的方法。

市场概况
预测期 2026-2030
2024 年市场规模 68亿美元
2030 年市场规模 116.8 亿美元
2025-2030 年复合年增长率 9.40%
成长最快的领域 癌症
最大的市场 北美洲

主要市场驱动因素

癌症和自体免疫疾病发生率上升

主要市场挑战

复杂设计与製造

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球双特异性抗体市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按适应症（癌症、发炎和自体免疫疾病、其他）
    • 按地区
    • 按公司分类（2024）
  • 产品市场图
    • 按适应症
    • 按地区

第 6 章：北美双特异性抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第 7 章：欧洲双特异性抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区双特异性抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲双特异性抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲双特异性抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 科威特

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 合併与收购
  • 产品发布

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • Akeso Inc
  • Janssen (Johnson & Johnson Private Limited)
  • Taisho Pharmaceutical Co Ltd
  • Immunocore Ltd

第 15 章：策略建议

第16章 调査会社について・免责事项

简介目录
Product Code: 17639

Global Bispecific Antibodies Market was valued at USD 6.80 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.40% through 2030. The global bispecific antibodies market has been witnessing significant growth and innovation in the biopharmaceutical industry. Bispecific antibodies are a class of therapeutic proteins designed to simultaneously target two different antigens, providing a unique approach to treating various diseases, including cancer and autoimmune disorders.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.80 Billion
Market Size 2030USD 11.68 Billion
CAGR 2025-20309.40%
Fastest Growing SegmentCancer
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Cancer and Autoimmune Diseases

The global bispecific antibodies (BsAbs) market is experiencing rapid expansion, primarily driven by the increasing incidence of cancer and autoimmune diseases worldwide. This trend is significantly boosting the demand for innovative, targeted biologics, positioning bispecific antibodies as a key therapeutic solution. In 2022, global cancer statistics revealed significant healthcare and economic challenges, with approximately 20 million new cancer cases diagnosed and 9.7 million cancer-related deaths recorded worldwide. The prevalence of cancer survivors within five years of diagnosis reached 53.5 million, underscoring the growing burden on healthcare systems to provide long-term care and support. Epidemiological data indicates that 1 in 5 individuals will develop cancer during their lifetime, with gender-specific mortality rates highlighting a higher risk among men (1 in 9) compared to women (1 in 12). These figures emphasize the critical need for innovative therapeutic solutions, early detection strategies, and scalable treatment options to address the rising global cancer burden. This rise is attributed to aging populations, lifestyle changes, and environmental factors. The growing cancer burden is increasing demand for advanced, highly effective therapies, which is propelling the adoption of bispecific antibodies in oncology. Unlike traditional monoclonal antibodies (mAbs), bispecific antibodies can simultaneously bind to two different antigens, enhancing tumor cell killing while reducing immune evasion. BsAbs can recruit and activate T cells or NK cells to attack tumor cells, offering a powerful alternative to standard chemotherapy and single-target biologics. Many cancer therapies face resistance over time, but BsAbs help overcome resistance mechanisms by targeting multiple pathways. BsAbs provide a more accessible and cost-effective option compared to personalized CAR-T therapies, which require complex manufacturing processes.

Key Market Challenges

Complex Design and Manufacturing

One of the primary challenges in the bispecific antibodies market is the complexity of their design and manufacturing processes. Creating bispecific antibodies that can simultaneously bind to two distinct molecules or cells requires precise engineering. The intricacies of their structure can lead to manufacturing challenges, impacting scalability, production costs, and consistency in quality.

Key Market Players

  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • Akeso Inc
  • Janssen (Johnson & Johnson Private Limited)
  • Taisho Pharmaceutical Co Ltd
  • Immunocore Ltd

Report Scope:

In this report, the Global Bispecific Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bispecific Antibodies Market, By Indication:

  • Cancer
  • Inflammatory & Autoimmune Disorders
  • Others

Bispecific Antibodies Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibodies Market.

Available Customizations:

Global Bispecific Antibodies market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bispecific Antibodies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 5.2.2. By Region
    • 5.2.3. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Indication
    • 5.3.2. By Region

6. North America Bispecific Antibodies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bispecific Antibodies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
    • 6.3.2. Canada Bispecific Antibodies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
    • 6.3.3. Mexico Bispecific Antibodies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication

7. Europe Bispecific Antibodies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bispecific Antibodies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
    • 7.3.2. United Kingdom Bispecific Antibodies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
    • 7.3.3. France Bispecific Antibodies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
    • 7.3.4. Italy Bispecific Antibodies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
    • 7.3.5. Spain Bispecific Antibodies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication

8. Asia-Pacific Bispecific Antibodies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 8.2.2. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bispecific Antibodies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
    • 8.3.2. Japan Bispecific Antibodies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
    • 8.3.3. India Bispecific Antibodies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
    • 8.3.4. Australia Bispecific Antibodies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
    • 8.3.5. South Korea Bispecific Antibodies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication

9. South America Bispecific Antibodies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 9.2.2. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bispecific Antibodies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
    • 9.3.2. Argentina Bispecific Antibodies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
    • 9.3.3. Colombia Bispecific Antibodies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication

10. Middle East and Africa Bispecific Antibodies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
    • 10.2.2. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bispecific Antibodies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
    • 10.3.2. Saudi Arabia Bispecific Antibodies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
    • 10.3.3. UAE Bispecific Antibodies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
    • 10.3.4. Kuwait Bispecific Antibodies Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Amgen Inc
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. F. Hoffmann-La Roche Ltd
  • 14.3. Genentech Inc
  • 14.4. Akeso Inc
  • 14.5. Janssen (Johnson & Johnson Private Limited)
  • 14.6. Taisho Pharmaceutical Co Ltd
  • 14.7. Immunocore Ltd

15. Strategic Recommendations

16. About Us & Disclaimer